Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report)'s stock price dropped 4.9% during trading on Thursday . The company traded as low as $1.44 and last traded at $1.37. Approximately 18,592 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 247,615 shares. The stock had previously closed at $1.44.
Repare Therapeutics Stock Performance
The business has a 50-day moving average of $1.39 and a 200-day moving average of $1.26. The stock has a market capitalization of $60.90 million, a price-to-earnings ratio of -0.47 and a beta of 0.84.
Institutional Trading of Repare Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC boosted its holdings in Repare Therapeutics by 35.6% during the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company's stock valued at $624,000 after acquiring an additional 168,230 shares during the period. Affinity Asset Advisors LLC boosted its stake in shares of Repare Therapeutics by 100.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company's stock valued at $197,000 after buying an additional 100,000 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Repare Therapeutics by 2,144,950.0% in the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company's stock valued at $112,000 after buying an additional 85,798 shares during the period. Lynx1 Capital Management LP purchased a new position in shares of Repare Therapeutics in the 4th quarter valued at about $104,000. Finally, Blue Owl Capital Holdings LP boosted its stake in shares of Repare Therapeutics by 2.1% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,443,659 shares of the company's stock valued at $4,511,000 after buying an additional 71,160 shares during the period. 85.09% of the stock is owned by institutional investors and hedge funds.
About Repare Therapeutics
(
Get Free Report)
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
Featured Stories
Before you consider Repare Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repare Therapeutics wasn't on the list.
While Repare Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
